In contrast, the small molecule dasatinib, which inhibits both EphB4 and its partner PDGFRβ, resulted in a significant inhibition of in vitro tumor cell viability as well as decreased in vivo tumor growth and significantly prolonged survival [213]. Here, PDGFRB is linked to neoplasm.